Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections

References

• Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia. 2021;64:2359–2366.
   PubMed Web of Science ®Google Scholar
• Waldrop G, Zhong J, Peters M, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. J Diabetes Complications. 2018;32:113–122.
   PubMed Web of Science ®Google Scholar
• Sfairopoulos D, Liatis S, Tigas S, et al. Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones (Athens). 2018;17:333–350.
   PubMedGoogle Scholar
• Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
   PubMed Web of Science ®Google Scholar
• Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes. Expert Opin Pharmacother. 2008;9:343–349.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int J Clin Pract. 2007;61:1949–1956.
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Liberopoulos E, et al. High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. Atherosclerosis. 2016;247:58–63.
   PubMed Web of Science ®Google Scholar
• Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009;338:310–318.
   PubMed Web of Science ®Google Scholar
• Abate N, Sallam HS, Rizzo M, et al. Resistin: an inflammatory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr Pharm Des. 2014;20:4961–4969.
   PubMed Web of Science ®Google Scholar
• Stoian AP, Banerjee Y, Rizvi AA, et al. Diabetes and the COVID-19 pandemic: how insights from recent experience might guide future management. Metab Syndr Relat Disord. 2020;18:173–175.
   PubMed Web of Science ®Google Scholar
• Goedecke JH, Utzschneider K, Faulenbach MV, et al. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism. 2010;59:1341–1350.
   PubMed Web of Science ®Google Scholar
• Bayram F, Kocer D, Gundogan K, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8:206–216.
   PubMed Web of Science ®Google Scholar
• Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39:472–485.
   PubMed Web of Science ®Google Scholar
• Kanasaki K, Qu S, and Yamamoto F, et al. The Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opin Drug Saf. In press.
   Google Scholar
• Ito T, Naito Y, Shimmoto N, et al. Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance. Expert Opin Drug Saf. 2021;20:363–372.
   PubMed Web of Science ®Google Scholar
• Watada H, Yamauchi T, Yamamoto F, et al. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Expert Opin Drug Saf. 2020;19:1193–1202.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Murayama H, Shinfuku Y, et al. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. Expert Opin Drug Saf. 2020;19:625–631.
   PubMed Web of Science ®Google Scholar
• Shibuki K, Shimada S, Aoyama T. Meta-analysis of 11 heterogeneous studies regarding dipeptidyl peptidase 4 inhibitor add-on therapy for type 2 diabetes mellitus patients treated with insulin. J Diabetes Res. 2020;2020:6321826.
   PubMed Web of Science ®Google Scholar
• Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. 2019;18:112.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al.; ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Alguwaihes A, Leon JLA, et al.; CAPTURE Study Investigators. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20:154.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Nikolic D, Patti AM, et al. GLP-1 receptor agonists and reduction of cardiometabolic risk: potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2814–2821.
   PubMed Web of Science ®Google Scholar
• Chmelík Z, Vaclová M, Lánská V, et al. Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic. Cent Eur J Public Health. 2020;28:114–119.
   PubMed Web of Science ®Google Scholar
• Kovarnik T, Chen Z, Mintz GS, et al. Plaque volume and plaque risk profile in diabetic vs. non-diabetic patients undergoing lipid-lowering therapy: a study based on 3D intravascular ultrasound and virtual histology. Cardiovasc Diabetol. 2017;16:156.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Nikfar S, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168:5437–5447.
   PubMed Web of Science ®Google Scholar
• White HD, Stewart RAH, Dalby AJ, et al.; STABILITY Investigators. In patients with stable coronary heart disease,low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. Am Heart J. 2020;225:97–107.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S111–S124.
   PubMed Web of Science ®Google Scholar